
GSK-923295

产品编号: D51519

CAS: 1088965-37-0

分子式: C₃₂H₃₈ClN₅O₄

纯度: ≥98%

InChi: InChI=1S/C32H38ClN5O4/c1-20(2)42-29-13-12-24(16-27(29)33)32(41)35-25(17-34-30(40)19-37(4)5)15-22-8-10-23(11-9-22)28-18-38-14-6-7-26(21(3)39)31(38)36-28/h6-14,16,18,20-21,25,39H,15,17,19H2,1-5H3,(H,34,40)(H,35,41)/t21-,25-/m0/s1

InChi Key: WHMXDBPHBVLRC-OFVILXPXSA-N

Smiles: CN(C)CC(=O)NC[C@H](CC1C=CC(=CC=1)C1=CN2C=CC=C([C@H](C)O)C2=N1)NC(=O)C1=CC(Cl)=C(C=C1)OC(C)C

外观: 固体粉末

作用通路: Apoptosis

溶解性: Soluble in DMSO, not in water

保存条件: Powder: -20°C for 3 years ;In solvent: -80°C for 1 year.

产品介绍: GSK-923295, also known as GSK-923295A, is a novel antimitotic inhibitor of centromere-associated protein E (CENP-E) with potential anticancer activity. GSK-923295A demonstrated significant antitumor activity against solid tumor models, inducing CRs in Ewing sarcoma, rhabdoid, and rhabdomyosarcoma xenografts. Clinical study showed that GSK-923295 had dose-proportional pharmacokinetics and a low number of grade 3 or 4 adverse events. The observed incidence of myelosuppression and neuropathy was low. Further investigations may provide a more complete understanding of the potential for GSK-923295 as an antiproliferative agent.